Nano-secondary antibody-Drug conjugates
AlpVHHs offers a new generation of Nano-Secondary antibody-drug conjugates with MMAE, MMAF, DXD or PBD for antibody internalization assays.
The use of Nano-Secondary antibody-drμg conjμgates (Nano-Secondary ADCs) in cell-based cytotoxicity assays is a rapid and cost-effective alternative for pre-screening candidate ADC monoclonal antibodies against tumor cells.
Nano-Secondary ADCs are highly specific and minimally toxic to cells in the absence of primary antibodies, and there is no significant change in primary antibody activity when the conjμgated secondary antibody is present.
Overview:
● Engineered high-affinity VHH nanobody conjugates
● Target Fc or CH1 fragments of human and mouse IgG
● Ready-to-use for flow cytometry, confocal imaging, and live-cell analysis
Functional Cytotoxicity-Based Internalization Screening
● VHH nano-secondary conjugated with potent cytotoxic payloads: MMAE, MMAF, DM1, DXD, Duocarmycin, PBD
● Evaluate internalization-dependent cytotoxicity
● Compare internalization efficiency among multiple antibody candidates
● Support high-throughput screening in tumor cell models
Ideal for rapid pre-selection of internalizing antibodies before formal ADC development.
Technical Advantages:
● High sensitivity with low background
● Compatible with multiple IgG subtypes
● Simplified workflow for high-throughput assays
All Products
